Selexys is a pharmaceutical company that developed a platform of Selectin Inhibition Technology consisting of therapies that target P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin to treat pain among those with sickle cell disease.
Year Founded: 2005
Year Partnered: 2009
Fund: Accelerate, Oklahoma Seed Capital Fund
Acquired in 2017 by Novartis